S100A7 is highly expressed in ER?- invasive carcinoma, as well as in high grade ductal carcinomas in situ (DCIS), and therefore may play an important role in breast cancer progression and metastasis. Our preliminary studies indicate that S100A7 has differential effects on ER?+ and ER?- cells;it enhances growth and metastasis in ER?- and inhibits growth in ER?+ breast cancer cells. However, it remains to be determined if and how S100A7 modulates differential effects in ER?+ and ER?- breast cancer subtypes. Our central hypothesis is that the differential effects of S100A7 are a result of two different pathways: in ER?-, it may modulate the tumor microenvironment by binding to receptor for advance glycation end products (RAGE) and transactivating EGFR;in ER?+ cells, it may regulate the 2-catenin pathway. The mortality of patients is significantly caused by the invasive characteristics of ER?-, especially in triple-negative breast cancers, and the development of drug resistance in ER?+ breast cancers;as a result, understanding how S100A7 may modulate differential effects in ER?- and ER?+ breast cancers is of fundamental importance. To this end, we will use an innovative, multi-disciplinary approach to analyze the role and molecular mechanisms of S100A7, taking advantage of transgenic and knockout mouse model systems.
In Aim 1, we will further analyze S100A7 expression in breast cancer tissue microarrays in different grades and subtypes, especially triple-negative breast cancers.
In Aim 2, we will further characterize the role of S100A7 in modulating the growth and metastasis of ER?+ and ER?- cells in in vivo mouse models.
In Aim 3, we will analyze the role of S100A7 in breast cancer progression and metastasis in transgenic and knockout mouse model systems. Finally, in Aim 4, we will delineate the S100A7-mediated molecular mechanisms that enhance growth and metastasis of ER?- cells and inhibit cell proliferation and migration of ER?+ cells. Insight gained from these studies may help in developing novel and innovative therapies for highly invasive ER?- and drug resistant ER?+ breast cancers.
S100A7 is highly expressed in both the aggressive ER?- and high grade ductal carcinoma in situ (DCIS) breast cancer subtypes. However, not much is known about its role in the development and progression of breast cancer. The proposed studies will determine the molecular mechanism by which S100A7 enhances growth and metastasis in ER?- and inhibits growth in ER?+ cells. Understanding the differential role of S100A7 in ER?- and ER?+ breast cancers may provide novel insights for prevention and treatment of highly aggressive and difficult to treat ER?- breast cancers, as well as ER?+ drug resistant breast cancers. In addition, these studies will also provide information about S100A7 expression in different grades and types of breast cancers, especially ER?- basal-type breast cancers.
|Elbaz, Mohamad; Ahirwar, Dinesh; Ravi, Janani et al. (2017) Novel role of cannabinoid receptor 2 in inhibiting EGF/EGFR and IGF-I/IGF-IR pathways in breast cancer. Oncotarget 8:29668-29678|
|Ravi, Janani; Elbaz, Mohamad; Wani, Nissar A et al. (2016) Cannabinoid receptor-2 agonist inhibits macrophage induced EMT in non-small cell lung cancer by downregulation of EGFR pathway. Mol Carcinog 55:2063-2076|
|Zhao, Helong; Ahirwar, Dinesh K; Oghumu, Steve et al. (2016) Endothelial Robo4 suppresses breast cancer growth and metastasis through regulation of tumor angiogenesis. Mol Oncol 10:272-81|
|Nasser, Mohd W; Wani, Nissar Ahmad; Ahirwar, Dinesh K et al. (2015) RAGE mediates S100A7-induced breast cancer growth and metastasis by modulating the tumor microenvironment. Cancer Res 75:974-85|
|Elbaz, Mohamad; Nasser, Mohd W; Ravi, Janani et al. (2015) Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of Cannabidiol in breast cancer. Mol Oncol 9:906-19|
|Powell, Catherine A; Nasser, Mohd W; Zhao, Helong et al. (2015) Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stability. Oncotarget 6:6373-85|
|Zhao, Helong; Wilkie, Tasha; Deol, Yadwinder et al. (2015) miR-29b defines the pro-/anti-proliferative effects of S100A7 in breast cancer. Mol Cancer 14:11|
|Nasser, Mohd W; Elbaz, Mohamad; Ahirwar, Dinesh K et al. (2015) Conditioning solid tumor microenvironment through inflammatory chemokines and S100 family proteins. Cancer Lett 365:11-22|
|Wani, Nissar; Nasser, Mohd W; Ahirwar, Dinesh K et al. (2014) C-X-C motif chemokine 12/C-X-C chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment. Breast Cancer Res 16:R54|
|Ravi, Janani; Sneh, Amita; Shilo, Konstantin et al. (2014) FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway. Oncotarget 5:2475-86|
Showing the most recent 10 out of 16 publications